To address this limitation, research has concentrated on many strategies, including identifying and developing DPP-IV inhibitors 43,44 , altering the structural makeup of GLP-1, searching for structural analogues that are more resistant to DPP-IV cleavage 45 , and increasing its hydrodynamic radius ( R h) above the glomerular filtration cutoff by conjugating it to proteins such as transferrin 46 , albumin 47 , and elastin-like polypeptides 48
Elucidating the underlying cellular and molecular mechanisms could potentially usher in the development of new generations of incretin mimetics with enhanced efficacy and fewer adverse effects
The distinction of rate is clinically important
Interestingly, GLP-2 administration leads to a reduction in PTH levels in people with an intact intestine, but not in those with short bowel syndrome, 63 indicating that an intact small intestine is required for GLP-2 mediated suppression of PTH secretion